APA (7th ed.) Citation

Jamnitski, A., Bartelds, G. M., Nurmohamed, M. T., van Schouwenburg, P. A., van Schaardenburg, D., Stapel, S. O., . . . Wolbink, G. J. (2011). The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Annals of the rheumatic diseases, 70(2), 284-288. https://doi.org/10.1136/ard.2010.135111

Chicago Style (17th ed.) Citation

Jamnitski, Anna, Geertje M. Bartelds, Michael T. Nurmohamed, Pauline A. van Schouwenburg, Dirkjan van Schaardenburg, Steven O. Stapel, Ben A C. Dijkmans, Lucien Aarden, and Gerrit Jan Wolbink. "The Presence or Absence of Antibodies to Infliximab or Adalimumab Determines the Outcome of Switching to Etanercept." Annals of the Rheumatic Diseases 70, no. 2 (2011): 284-288. https://doi.org/10.1136/ard.2010.135111.

MLA (9th ed.) Citation

Jamnitski, Anna, et al. "The Presence or Absence of Antibodies to Infliximab or Adalimumab Determines the Outcome of Switching to Etanercept." Annals of the Rheumatic Diseases, vol. 70, no. 2, 2011, pp. 284-288, https://doi.org/10.1136/ard.2010.135111.